reuters.com · 17 jul

GSK to halt further development of cough drug after missing main goal

GSK on ‌Friday said it had decided not to develop ​its experimental drug ​to treat refractory chronic ⁠cough further after it ​did not meet ​one of its main goals in a late-stage trial.

zacks.com · 14 jul

GSK's Jemperli Delivers Promising Interim Data in Rectal Cancer

GSK reports positive interim phase II AZUR-1 data as Jemperli meets the primary endpoint in rectal cancer, supporting potential regulatory filings.

gurufocus.com · 13 jul

Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (“KSF”) are investigating the propo

businesswire.com · 13 jul

Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nuvalent, Inc. (NasdaqGS: NUVL) to GSK plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of Nuvalent will receive $124.00 in cash for each share of Nuvalent that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate.

proactiveinvestors.com · 13 jul

UBS keeps GSK at 'neutral' with focus on chief executive's strategy update

UBS expects investors to pay little attention to GSK PLC's (LSE:GSK, NYSE:GSK) second-quarter results, with focus shifting instead to a strategy update from...

proactiveinvestors.co.uk · 13 jul

UBS keeps GSK at 'neutral' with focus on chief executive's strategy update

UBS expects investors to pay little attention to GSK PLC's (LSE:GSK, NYSE:GSK) second-quarter results, with focus shifting instead to a strategy update from new chief executive Luke Miels. The bank reiterated its 'neutra'l rating on GSK ahead of results and a capital markets day due on 28 July.

reuters.com · 13 jul

GSK's Jemperli meets main goal in mid-stage rectal cancer trial

GSK said on Monday its cancer drug Jemperli met the ​primary goal of a mid-stage trial, with ‌a clinically significant rate of patients showing no detectable signs of cancer for one year or more after treatment for a specific type of ​locally advanced rectal cancer.

reuters.com · 10 jul

GSK's targeted cancer therapy shows positive results in late-stage study

British drugmaker ​GSK's experimental ‌drug for treating ​patients ​with advanced or ⁠relapsed ​small-cell ​lung cancer showed positive ​results ​in a late-stage ‌trial ⁠on Friday.